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Introduction: Cytochrome P 450 enzymes (CYPs) were presumed 
to play a role in the oxidation of intermediate metabolites of busul-
fan (Bu). In vitro elucidation of involvement of CYPs in the oxi-
dation of Bu metabolites is cumbersome due to the volatile nature 
of tetrahydrothiophene and nonavailability of sensitive quantita-
tion methods. This study is aimed at exploring the association of 
CYP2C9, CYP2C19, CYP2B6, FMO genotypes, and sulfolane (Su) 
levels in children undergoing hematopoietic stem cell transplantation 
(HSCT).The relation of genotypes with the outcomes of HSCT was 
also explored.
Patients (or Materials) and Methods: Sixty-six children receiving IV 
Bu-based myeloablative conditioning regimen were genotyped for 
common functional variant alleles in CYP2C9 (*2 and *3), CYP2C19 
(*2 and *17), FMO3 (rs2266780, rs2266782 and rs1736557) and 
CYP2B6 (*5 and *9). Plasma levels of Bu and its metabolite Su were 
measured after dose 9 from a subset of 44 patients for whom plasma 
samples after dose 9 were available. The ratio of Bu to Su was taken 
as a metabolic ratio (MR) to compare among genotype groups. The 
MRs (Bu/Su), Bu and Su levels between different genotype groups 
were compared using nonparametric tests. The distribution of age, 
and gender between the groups was compared using t test and chi-
square test, respectively. Cumulative incidence of overall survival and 
event-free survival were estimated using Kaplan-Meier curves and 
log-rank test was used to compare the difference between genotype 
groups or groups divided on the basis of MR, in a univariate analysis. 
Multivariate analysis was performed using cox-regression analysis.
Results: Higher metabolic ratios (MRs, Bu/Su) were observed in 
CYP2C9*2 and *3 allele carriers (mean [SD], 7.8 [3.6] Vs 4.4 [2.2]; 
P = 0.003). Lower event-free survival was seen in patients with MR 
above the median 5 (40% vs 79%; P = 0.009) and carrying reduced 
function alleles of CYP2B6 (40% vs 84%; P = 0.005).
Conclusion: This study suggests the role of the CYP2C9 in the oxi-
dation reactions of THT and CYP genotypes along with Bu MRs 
to be important at predicting outcomes of Bu based myeloablative 
conditioning before HSCT.
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Introduction: Nevirapine (NVP) is a non-nucleoside reverse tran-
scriptase inhibitor (NNRTI) widely used in antiretroviral therapy 
(ART) in sub-Saharan Africa. Approximately 5% of patients 
receiving NVP-containing regimens develop hypersensitivity reac-
tions (HSRs). These can manifest as more severe reactions includ-
ing Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis 
(TEN), and hepatotoxicity. Various human leukocyte antigen (HLA) 
alleles have been associated to NVP-induced HSRs in populations 
of differing ethnicity. Carriage of HLA-C*04:01 is associated with 
an increased risk of SJS in our Malawian cohort. We investigated 
whether expression levels of miR-148a, a microRNA known to regu-
late HLA-C expression, differ in serum samples from hypersensitive 
and tolerant patients. The aim of the study was to identify the role 
of posttranscriptional regulation of HLA-C expression in HLA-
associated NVP-induced HSRs.
Patients (or Materials) and Methods: A total of 1117 HIV-positive 
patients in Malawi treated with a NVP-containing regimen were 
recruited prospectively. Of these, 57 patients developed NVP-induced 
HSRs. MicroRNA expression was analyzed using TaqMan probe–
based qPCR in available serum samples of 41 tolerant and 33 hyper-
sensitive patients. Expression levels were compared in hypersensitive 
patients at baseline (n = 19) and during the acute phase of the reac-
tion (n = 26). Tolerant baseline (n = 25) and week 6 (n = 27) samples 
were used as controls. Data were analyzed using nonparametric tests.
Results: There was no significant difference in the baseline expres-
sion of miR-148a between tolerant and hypersensitive patients. In 
our cohort, miR-148a expression showed a 4.6-fold increase in acute 
hypersensitive samples, when compared with baseline hypersensitive 
(P = 0.008). This was not observed in samples from tolerant patients.
Conclusion: Our study has identified an increase in miR-148a 
expression levels in serum samples from Malawian nevirapine 
hypersensitive patients during the acute phase. The reason(s) for the 
change in expression during the acute phase are unclear but may be 
related to the ongoing inflammation associated with a HSR. Further 
investigation is required to elucidate the mechanism of the rise in 
microRNA levels and any implications this may have on the severity 
and duration of the HSR.
Disclosure of Interest: None declared.
PP123—taRget gene evaluation of two 
miRnas diffeRently exPRessed in focal 
and non-focal bRain tissue of theRaPy-
Resistant ePilePsy Patients
S. Haenisch1,2*; A. Chhibber1; I. Cascorbi2; and D.L. Kroetz1
1School of Pharmacy, Department of Bioengineering and 
Therapeutic Sciences, University of California, San Francisco, 
California; and 2Institut of Experimental and Clinical 
Pharmacology, University Hospital Schleswig-Holstein, Kiel, 
Germany
Introduction: Resistance to anticonvulsants affects one third of all 
epilepsy patients. Limited bioavailability of the drug at the target site 
caused by increased expression of efflux transporters on the blood 
brain barrier or alterations of target genes as well as seizure-induced 
neural reorganization are potential mechanisms for therapy resist-
ance. There is increasing evidence that expression of microRNAs 
(miRNAs) is deregulated in neuronal disorders. We hypothesize that 
an altered miRNA regulation of target genes is involved in drug 
resistance in epilepsy.
Patients (or Materials) and Methods: Hippocampal focal and corti-
cal nonfocal brain tissue samples from 13 patients diagnosed with 
MTS (mesial temporal sclerosis) who underwent neurosurgery have 
been screened for miRNA expression using TaqMan® low-density 
arrays. To compare miRNA expression between brain regions, a 
Mann-Whitney U test was performed using R (Bioconductor). In 
silico approaches for both a hypothesis-based (efflux-transporter 
and target gene) as well as a hypothesis-free approach were used 
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to filter for potential phenotype-relevant target genes. After cloning 
3’-UTR sequences containing predicted miRNA binding sites into 
psiCHECK2 or pmiRGLO vectors reporter gene assays were per-
formed to confirm RNA interference of selected candidate miRNAs 
with their respective target genes.
Results: Of 754 miRNAs, 201 were detected in both tissue types. 
Two miRNAs were differentially expressed in the hippocampus 
relative to the cortex (miR-34c-5p: 7.2-fold higher [q = 0.01], miR-
212-3p: 3.8-fold lower [q = 0.01]). Bioinformatic analysis and fil-
tering for target genes identified 9 genes important for drug efflux, 
neuronal regulation, and signal transmission. Reporter gene experi-
ments confirmed 3 target genes posttranscriptionally regulated by 
miR-34c-5p (GABBR2, GABRA3, GRM7) and 3 target genes regu-
lated by miR-212 (ABCG2, SOX11, ADCY1).
Conclusion: Differential regulation of 2 miRNAs could contribute 
to an altered function of several genes resulting not only in an imbal-
anced neuronal excitability but also in impaired neural differentia-
tion and accelerated drug export. These data suggest multifactorial 
alterations involving miRNA-mediated regulation leading to phar-
macoresistance in epilepsy.
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Introduction: Tolperisone, which is indicated in the treatment of acute 
muscle spasms in back pain and spasticity in neurologic diseases, is a 
centrally acting muscle relaxant. Although the metabolism of tolperisone 
is primarily mediated by CYP2D6, CYP2C19, CYP1A2, and CYP2B6 
are also involved in the biotransformation of tolperisone. Among 3 
drug-metabolizing enzymes, CYP2C19 is a highly polymorphic enzyme. 
The aim of this study was to investigate the effects of CYP2C19 genetic 
polymorphism on the pharmacokinetics of tolperisone.
Patients (or Materials) and Methods: Twenty-six healthy Korean 
subjects were selected and divided into 3 different groups according 
to CYP2C19 genotype, CYP2C19EM (CYP2C19*1/*1, n = 12), 
CYP2C19IM (CYP2C19*1/*2 or *1/*3, n = 7), and CYP2C19PM 
(CYP2C19*2/*2, *2/*3 or *3/*3, n = 7). After overnight fasting, 
each subject received a single 150-mg oral dose of tolperisone. Blood 
samples were collected up to 12 hours after drug intake, and plasma 
concentrations of tolperisone were measured by using LC-MS/MS 
analytical system.
Results: Cmax in CYP2C19PM group was significantly higher 
than that in CYP2C19IM and CYP2C19EM (P = 0.0017 for 
all). AUCinf in CYP2C19PM was also significantly higher than 
that in CYP2C19IM and CYP2C19PM group (P < 0.001 for all). 
Corresponding values for tolperisone in CYP2C19EM and IM groups 
were almost similar (P > 0.05). Apparent oral clearance (CL/F) of 
tolperisone in CYP2C19PM group was 84% lower than that in 
CYP2C19IM group (618 [379] vs 2900 [1343] L/h; P = 0.0010). 
Differences in other parameters of tolperisone between 3 genotype 
groups were not statistically significant.
Conclusion: In Korean healthy subjects, pharmacokinetics of tolp-
erisone are not only influenced by CYP2D6 genotypes but also influ-
enced by CYP2C19 genotypes. Particularly, CYP2C19PM subjects 
had markedly increased plasma concentration of tolperisone com-
pared with CYP2C19EM or CYP2C19IM subjects.
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Introduction: Carbamazepine (CBZ) causes hypersensitivity reac-
tions in a small proportion of patients. There is strong evidence that 
specific human leukocyte antigen (HLA) alleles are associated with 
a higher risk of developing CBZ-induced hypersensitivity. HLA-
A*3101 represents the latest example and is associated with several 
clinical phenotypes of CBZ-induced hypersensitivity in Caucasian 
and Japanese patients. In this study, we aimed to determine whether 
HLA-A*31:01 is functionally implicated in the development of a 
drug-specific immune response in our patient.
Patients (or Materials) and Methods: Peripheral blood mononuclear 
cells (PBMCs) were isolated from a patient with CBZ hypersensitivity 
and the presence of drug-responsive T cells confirmed in vitro using 
the lymphocyte transformation test (LTT). The study was approved 
by the local ethics committee and informed consent was obtained 
from the patient. Drug-specific T cells were enriched in a 4-week 
induction culture and their reactivity tested with enzyme-linked 
immunospot (ELISpot) technique and 51Cr-release assay. T-cell 
clones (TCCs) were generated by serial dilution; characterization 
included CD phenotype, HLA restriction and cytokine profile.
Results: PBMCs responded to CBZ in the LTT with a stimulation 
index (SI) of 15.9. After the 4-week enrichment culture, T-cells were 
shown to secret Interferon-γ (IFN-γ ) and kill 51Cr-loaded target cells 
when exposed to CBZ. Thirty-two CBZ-specific TCCs were gener-
ated; they secreted IFN-γ , interleukin-13 and cytolytic molecules such 
as granzyme B, perforin, and FasLigand. The majority of TCCs were 
CD4+ and T-cell activation was restricted by HLA class II alleles, 
i.e. HLA-DR and -DP. These TCCs proliferated in the presence of 
both CBZ and antigen presenting cells (APCs) expressing HLA-
A*31:01 and HLA-DRB1*04:04, but also in the presence of HLA-
DRB1*04:04+ APCs lacking HLA-A*31:01. HLA-DRB1*04:04 is 
known to be part of a common haplotype with HLA-A*31:01 in 
Caucasians.
Conclusion: We were able to stimulate a secondary immune response 
to CBZ in vitro using lymphocytes from a HLA-A*31:01+ hypersen-
sitive patient. CBZ-specific T cells of CD4+ phenotype were restricted 
by HLA class II alleles, and proliferated in the presence of CBZ and 
HLA-DRB1*04:04+ A*31:01- APCs revealing that a common hap-
lotype may contribute to the multi-clonal response seen in patients 
with CBZ hypersensitivity. Further studies are needed to confirm 
the association.
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Introduction: Two algorithms for acenocoumarol stable dose pre-
diction have been recently published. The first, developed by the 
EU-PACT group includes demographic (age, sex, weight, height, 
amiodarone cotreatment) and genetic variables (genetic variants 
in CYP2C9 and VKORC1 genes). The second one has been devel-
oped by our group (HULP algorithm) in a cohort of 147 patients 
with thromboembolic disease (VTD), including clinic-demographic 
